 Home > Biochemistry News > Biotechnology News > FDA rejects approval of AstraZeneca's new application for Fasenra

FDA rejects approval of AstraZeneca's new application for Fasenra

 Last Update: 2022-05-22
 Source: Internet
 Author: User

Tags

chronic granulomatous disease symptoms

mass spec data

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationAspirin

AstraZeneca's Fasenra (benralizumab) hits a snag as it tries to expand its indications

Recently, the FDA issued a Complete Response Letter (Complete Response Letter) to AstraZeneca Fasenra's application for the treatment of nasal polyps, and rejected the application because the results of the Phase III trial OSTRO data were not convincing enough

In the clinical trial study called OSTRO, Fasenra met two co-primary endpoints and demonstrated a strong safety profile

Chronic rhinosinusitis with nasal polyps is a common disorder characterized by inflammation of the lining of the nose and sinus cavities

Fasenra is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and then attracts killer cells to the site to reduce polyps and inflammation

According to AstraZeneca's annual report, Fasenra's sales will reach $1.

AstraZeneca had hoped to take a slice of the market share of formidable rival Dupixent, but this time the FDA's rejection messenger Fasenra is at a disadvantage in the competition for anti-inflammatory biologics

Currently, AstraZeneca remains committed to bringing Fasenra's nasal polyp indication to market

Reference source: Sanofi Long wait for pivotal data on Sanofi's oral SERD ends in failure

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.